Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
Relmada Therapeutics (Nasdaq: RLMD), a late-stage biotechnology company focused on central nervous system diseases, has announced it will host a conference call and webcast on November 7, 2024 at 4:30 PM ET. The event will discuss business progress and financial results for the third quarter ended September 30, 2024. The company has provided dial-in numbers for US and international participants, along with a webcast option. A replay will be available in the Investors section of Relmada's website.
Relmada Therapeutics (Nasdaq: RLMD), un'azienda biotecnologica in fase avanzata focalizzata sulle malattie del sistema nervoso centrale, ha annunciato che ospiterà una conferenza telefonica e una diretta web il 7 novembre 2024 alle 16:30 ET. L'evento discuterà dei progressi aziendali e dei risultati finanziari per il terzo trimestre conclusosi il 30 settembre 2024. L'azienda ha fornito numeri di dial-in per i partecipanti statunitensi e internazionali, insieme a un'opzione per la diretta web. Sarà disponibile una registrazione nell'area Investitori del sito web di Relmada.
Relmada Therapeutics (Nasdaq: RLMD), una compañía de biotecnología en etapa avanzada enfocada en enfermedades del sistema nervioso central, ha anunciado que llevará a cabo una llamada de conferencia y una retransmisión web el 7 de noviembre de 2024 a las 4:30 PM ET. El evento discutirá el progreso empresarial y los resultados financieros del tercer trimestre que finalizó el 30 de septiembre de 2024. La compañía ha proporcionado números de acceso para participantes de EE. UU. e internacionales, junto con una opción de retransmisión web. Una repetición estará disponible en la sección de Inversores del sitio web de Relmada.
Relmada Therapeutics (Nasdaq: RLMD)는 중추신경계 질환에 초점을 맞춘 말기 생명공학 회사로, 2024년 11월 7일 오후 4시 30분 ET에 전화 회의 및 웹캐스트를 개최한다고 발표했습니다. 이번 이벤트에서는 2024년 9월 30일 종료된 3분기 비즈니스 진행 상황 및 재무 결과에 대해 논의할 것입니다. 회사는 미국 및 국제 참가자를 위한 다이얼 인 번호와 웹캐스트 옵션을 제공했습니다. Relmada의 웹사이트 투자자 섹션에서 재생이 가능합니다.
Relmada Therapeutics (Nasdaq: RLMD), une société de biotechnologie en phase avancée axée sur les maladies du système nerveux central, a annoncé qu’elle tiendra une conférence téléphonique et un webinaire le 7 novembre 2024 à 16h30 ET. L'événement discutera des progrès commerciaux et des résultats financiers pour le troisième trimestre se terminant le 30 septembre 2024. L'entreprise a fourni des numéros de composition pour les participants américains et internationaux, ainsi qu'une option de webinaire. Un replay sera disponible dans la section Investisseurs du site Web de Relmada.
Relmada Therapeutics (Nasdaq: RLMD), ein Biotechnologieunternehmen in der späten Entwicklungsphase, das sich auf Krankheiten des zentralen Nervensystems konzentriert, hat angekündigt, dass es am 7. November 2024 um 16:30 Uhr ET eine Telefonkonferenz und ein Webcast veranstalten wird. Bei der Veranstaltung werden Fortschritte im Geschäft und finanzielle Ergebnisse für das dritte Quartal, das am 30. September 2024 endete, besprochen. Das Unternehmen hat Einwahlnummern für US-amerikanische und internationale Teilnehmer sowie eine Webcast-Option bereitgestellt. Eine Wiederholung wird im Investorenbereich der Relmada-Website verfügbar sein.
- None.
- None.
CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.
| Conference Call and Webcast Information: | ||
| Date: | Thursday, November 7, 2024 at 4:30 PM ET | |
| Participant Dial-in (US): | 1-800-717-1738 | |
| Participant Dial-in (International): | 1-646-307-1865 | |
| Conference ID Code: | 60579 | |
| Webcast Access: | Click Here | |
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017 (esmethadone), is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.
Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@lifesciadvisors.com
FAQ
When will Relmada Therapeutics (RLMD) report Q3 2024 earnings?
How can investors access Relmada's (RLMD) Q3 2024 earnings call?
Will there be a replay available for Relmada's (RLMD) Q3 2024 earnings call?
